Indivior Share Discussion Threads

[maywillow] 24/9/2022 14:58

The expected timetable for the General Meeting, the Consolidation and the Additional US Listing is set out below:


Event


Expected time/date (see note 1)

Latest time and date for receipt of Forms of Proxy, eProxy appointment instruction and CREST electronic proxy appointment instruction


11.00 a.m. (London time) on September 28, 2022

Voting Record Time for the General Meeting for Indivior Shareholders


6.00 p.m. (London time) on September 28, 2022 (see note 2)

General Meeting


11.00 a.m. (London time) on September 30, 2022

Consolidation Record Time


6.00 p.m. (London time) on
October 7, 2022

Admission of New Ordinary Shares to listing on the premium listing segment of the Official List and to trading on the London Stock Exchange’s main market for listed securities and commencement of dealings in New Ordinary Shares


8.00 a.m. (London time) on
October 10, 2022

Expected date CREST accounts are to be credited with New Ordinary Shares in uncertificated form


October 10, 2022

Expected date for dispatch of definitive certificates for New Ordinary Shares in certificated form


October 17, 2022

Expected date for payment (where applicable) of fractional entitlements for New Ordinary Shares


October 21, 2022

Expected time and date for admission and commencement of dealings in Indivior Shares on a major US stock exchange


By 8.00 a.m. (New York time) on May 31, 2023

Expected date for issue of Indivior DIs to CREST participant accounts and crediting of CSN Facility accounts


On or around May 31, 2023

[disc0dave45] 24/9/2022 11:03

10th October new shares traded on LSE.

[ariane] 24/9/2022 09:19

Upcoming events on INDIVIOR PLC

September/30/2022 | 11:00am Shareholders Meeting

October/27/2022 Q3 2022 Earnings Release

October/27/2022 | 01:00pm Q3 2022 Earnings Call

[disc0dave45] 24/9/2022 08:40

Consolidations are generally viewed as being negative by the market, so wouldn't be surprised to see a drop prior to the consolidation date....a good entry / top up opportunity.

[gregmorg] 14/9/2022 12:34

My experience of the old days when share certificates were issued was that old certs were cancelled snd new ones issued. Digitally these days it’s probably very easily done with a central register.
As my holdings are spread over several accounts ,SIPP’s ISA’s main account etc I revised up any quantity nor exactly divided by 5! Saves any argument over numbers was my theory!

Barely makes much difference really

[gregmorg] 14/9/2022 11:10

Mm well, I admit I have dreamed of Indivior reaching £14 or indeed £15 a share. Unfortunately for me, my dream didn’t cover the consolidation aspect!

Even so, I am hopeful that continuing good results as per recent time will project the shares to beyond a record level which really means beyond £25 according to my arithmetic !
Nice thought that!
Not worried that some investors like penny shares for that is not a game for me. It was once and yes, it was exciting but often the follow on -devastating comes to mind!

LESG went from £3 approx to £99 ( now £80 approx ) so size doesn’t prevent momentum -both ways admittedly!
Rather hopeful the cannabis drug makes development progress this year so that more strings to the bow are added .

[casholaa] 08/9/2022 14:20

I've been in this situation before but I can't remember how it works. I don't know if they simply an amount of tradable shares with a broker capable of US trading or issue new ones.

[steeplejack] 08/9/2022 10:21

So we're going to have a 1:5 consolidation which will give a share price of well over £14 at current share prices.Whilst heavyweight prices in the US are popular (taken to reflect a successful past) the attitude in the UK is more parochial.UK punters have a penchant for penny stocks,taking some strange comfort in the fact that they hold a sizeable number of shares.....trust me,its true!So consolidations are not always that well received in the UK albeit that brokers are becoming more adept at making the updating of nominee accounts quicker and more seamless.

[waldron] 05/9/2022 15:46

September 5, 2022

Indivior PLC (the 'Company')

Publication of Circular and Notice of General Meeting

On July 28, 2022, the Board of Directors of the Company announced that, following consultation with institutional shareholders, it had decided to seek the approval of shareholders for an additional listing of Indivior Shares on a major US stock exchange (the "Additional US Listing").

Further to that announcement, the Company has today posted or made available to shareholders a circular (the "Circular") incorporating a notice of general meeting (the "General Meeting") regarding the Additional US Listing. In order to implement the Additional US Listing, shareholder approval is being sought (i) to adopt new articles of association and (ii) to effect a consolidation of Indivior's existing ordinary share capital at a ratio of one new ordinary share for every five existing ordinary shares (the "Consolidation"). Further details regarding the proposed new articles of association and the proposed Consolidation are set out in the Circular.

Copies of the following documents have been submitted to the FCA and will shortly be available for inspection at: hxxps://data.fca.org.uk/#/nsm/nationalstoragemechanism

- Circular incorporating the notice of General Meeting;
- Form of Proxy for the General Meeting; and
- Proposed amendments to the articles of association.

The Circular incorporating the notice of General Meeting and the proposed amendments to the articles of association can also be viewed on the Company's website at: www.indivior.com/en/investors/shareholder-information and will be available for inspection at the place of the General Meeting for at least 15 minutes before and during the General Meeting .

The General Meeting will be held on Friday September 30, 2022, at 11.00 a.m. at the offices of Freshfields Bruckhaus Deringer LLP, 100 Bishopsgate, London EC2P 2SR.

The expected timetable for the General Meeting, the Consolidation and the Additional US Listing is set out below:


Event Expected time/date
(see note 1)
Latest time and date for receipt of Forms 11.00 a.m. (London time)
of Proxy, eProxy appointment instruction on September 28, 2022
and CREST electronic proxy appointment
instruction
-------------------------
Voting Record Time for the General Meeting 6.00 p.m. (London time)
for Indivior Shareholders on September 28, 2022
(see note 2)
-------------------------
General Meeting 11.00 a.m. (London time)
on September 30, 2022
-------------------------
Consolidation Record Time 6.00 p.m. (London time)
on
October 7, 2022
-------------------------
Admission of New Ordinary Shares to listing 8.00 a.m. (London time)
on the premium listing segment of the on
Official List and to trading on the London October 10, 2022
Stock Exchange's main market for listed
securities and commencement of dealings
in New Ordinary Shares
-------------------------
Expected date CREST accounts are to be October 10, 2022
credited with New Ordinary Shares in
uncertificated form
-------------------------
Expected date for dispatch of definitive October 17, 2022
certificates for New Ordinary Shares
in certificated form
-------------------------
Expected date for payment (where applicable) October 21, 2022
of fractional entitlements for New Ordinary
Shares
-------------------------
Expected time and date for admission By 8.00 a.m. (New York
and commencement of dealings in Indivior time) on May 31, 2023
Shares on a major US stock exchange
-------------------------
Expected date for issue of Indivior DIs On or around May 31,
to CREST participant accounts and crediting 2023
of CSN Facility accounts
-------------------------


NOTES:

1) All dates and times are based on Indivior's current expectations and are subject to change. If any of the dates and/or times change, Indivior will give notice of the change by issuing an announcement through a Regulatory News Service.

2) Only those Indivior Shareholders entered on the register of members at 6.00 p.m. (London time) on September 28, 2022 or, if the General Meeting is adjourned, on the register of members at 6.00 p.m. on the day which is two business days before the time of the adjourned meeting, shall be entitled to attend and vote at the General Meeting in respect of the number of Indivior Shares registered in their name at that time.

[waldron] 05/9/2022 09:35

Transfer of Primary Listing

Spring 2023 earliest implementation


➤ If considered beneficial, further consultations on whether to move to
primary listing in US (by reducing UK listing to a standard listing) or cancel
UK listing outright

➤ Assessment would be informed by benefits demonstrated by additional US
listing in addition to fulsome shareholder consultation on its merits

➤ Requires 75% of majority shareholder approval (of votes cast)

➤ Extraordinary General Meeting (EGM) of shareholders

Proposed consultation on possible additional US listing

Current consultation focuses on an additional US listing; further assessment
of value of US primary /sole listing would follow if deemed appropriate
Additional US Listing

➤ Additional listing (alongside current LSE listing) on a major US exchange
(Nasdaq or NYSE)

➤ Requires 75% majority shareholder approval (of votes cast)


➤ Extraordinary General Meeting (EGM) of shareholders Considerations

➤ Spring 2023 earliest implementation

➤ Considerable period of preparation required

➤ If approved, requires Sarbanes Oxley compliance

[waldron] 05/9/2022 09:26

October 27, 2022

Q3 2022 Results Webcast

Time: 8:00 AM US EST / 13:00 GMT

[youngers] 05/9/2022 07:16

Aren’t we supposed to have egm this month for US listing. I’ve not seen any notice of the meeting yet?

[casholaa] 17/8/2022 19:45

Yup. Some sort of therapeutic is needed. Having said that, I can't see why or even how a pharmacy dispensing a drug that was prescribed by an independent third party doctor should be liable, it's baffling.

[timmy11] 17/8/2022 16:35

Pharmacy operators CVS, Walmart and Walgreens must pay a combined $650.6 million to two Ohio counties to address the damage done by the opioid epidemic, a federal judge ruled Wednesday.

The ruling by U.S. Judge Dan Polster in Cleveland comes after the first trial pharmacy chains have faced over the opioid crisis.

[casholaa] 29/7/2022 07:20

Get up there!

[gregmorg] 28/7/2022 12:54

Yup steady as you go as I see it. Yes, the upgraded revenue guidance is good to see but there's a cost. Spending more, on marketing in particular -as Indivior had previously indicated. Hopefully the market will get more excited as the months progress into the now formalised and provisionally planned early 2023 US listing. Interesting new product potential being explored and hopefully gradually developed. Fewer questions from analysts on the webcast this time.

[steeplejack] 28/7/2022 07:06

Those are very good results.US listing pencilled in for Spring 2023.Share consolidation to occur to facilitate that US listing.

[steeplejack] 28/7/2022 07:01

H1 / Q2 2022 Financial Highlights• H1 2022 total net revenue (NR) of $428m increased 12% (H1 2021: $381m); Q2 2022 total NR of $221m increased 10% (Q2 2021: $201m). Net revenue growth in each period was primarily driven by SUBLOCADE.• H1 2022 reported operating profit of $117m decreased 10% (H1 2021: $130m); Q2 2022 reported operating profit of $63m decreased 14% (Q2 2021: $73m). On an adjusted basis, H1 2022 operating profit of $114m decreased 3% (Adj. H1 2021: $117m). Adj. Q2 2022 operating profit of $60m decreased 9% (Adj. Q2 2021: $66m). Declines in both reported and adjusted operating profit in each period reflect the impact of an expected increase in operating expenses, mainly SG&A investments to grow SUBLOCADE and PERSERIS.• H1 2022 reported net income of $89m decreased 37% (H1 2021: $142m); Q2 2022 reported net income of $48m decreased 23% (Q2 2021: $62m). On an adjusted basis, H1 2022 net income of $86m decreased 1% (Adj. H1 2021 net income: $87m). Adj. Q2 2022 net income of $45m decreased 8% (Adj. Q2 2021: $49m).• Gross cash and investments totalled $1,015m at the end of Q2 2022 (FY 2021: $1,102m). See discussion of Group obligations in Notes 9 & 10.• Cash used in operations was $14m. Excluding exceptional litigation settlement payments of $108m, cash generated from operations was approximately $94m.

[sarkasm] 28/7/2022 06:57

Webcast Details

There will be a live webcast presentation at 13:00 BST (8:00 am EDT) hosted by Mark Crossley, CEO. The details are below. All materials will be available on the Group's website prior to the event at www.indivior.com .

Webcast link:

Participants may access the presentation telephonically by registering with the following link:

[...]

(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)

[steeplejack] 28/7/2022 06:52

“We delivered another strong performance in the second quarter driven by the team’s relentless focus on our strategic priorities as well as benefits from our incremental investments behind SUBLOCADE® (buprenorphine extended-release) and PERSERIS® (risperidone). Second quarter SUBLOCADE net revenue grew 61% to $98m, as our Organized Health System strategy resulted in broadened account access and increased depth of prescribing. Based on our stronger-than-expected H1 performance, we are increasing our full year guidance for SUBLOCADE to $390m to $420m. Our PERSERIS national expansion also continues to deliver against expectations with net revenue increasing 75% in the second quarter.
We continue to focus on delivering value for all shareholders as demonstrated by our disciplined capital allocation policy which has allowed us to maintain a strong and flexible balance sheet while also executing on the $100m share repurchase program announced in May. Additionally, we have completed extensive consultations with key stakeholders on the potential for an additional US listing and based on positive feedback we now intend to seek shareholder approval for this important strategic step at a September EGM.”

[waldron] 20/7/2022 10:59

Upcoming events on INDIVIOR PLC

July/28/2022 | 07:00am Interim 2022 Earnings Release

July/28/2022 | 01:00pm Interim 2022 Earnings Call

cheers Batty

take care

chuckle and cheers

[battyliveson] 20/7/2022 10:53

Earnings release next week.Hopefully that will give the share price some upwards momentum. I have been trading this between 280 and 320, and taken a small position hoping for a breakout (to the upside!).

B

[km18] 15/7/2022 11:06

...from a while ago...

Indivior Plc is engaged in developing medicines to treat addiction and serious mental illness in the UK. It focuses to build a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as new therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Considering the growing demand for medicine stemming from the pandemic, and rising need to tackle mental health, the firm managed to capitalise these opportunities and thereby profit rallied to £35m from (£13m) loss, resulting in an EPS Growth of 44.6%. Simultaneously, the firm enhanced its net cash position from £858m to £1,102m,  leading to an attractive P/FCF of 26.7. Despite the growing profitability, the firm is trading at a discount, illustrated by the P/E ratio of 14.4, which is lower than the healthcare P/E ratio of 26.3, thus the security is undervalued and is expected to surge in value, since Indivior’s P/B ratio robustly stands at 13.45.

Brief Analysis:

Operating profit = £35m, higher than previous period.
Net cash = £1,102m, above prior year.
P/FCF = 26.7, higher than sector benchmark.
P/B = 13.45, above industry threshold.
P/E = 14.4, relatively below healthcare sector valuation.
EPS Growth = 44.6%, substantially above its peers.

[casholaa] 24/6/2022 14:35

I found a link earlier which suggested a figure but I lost the link. I think it's all priced in anyway given that the patent issue was ruled upon around 2 years ago.